In This Article:
Futura Medical (LON:FUM) Full Year 2024 Results
Key Financial Results
-
Revenue: UK£13.9m (up 349% from FY 2023).
-
Net income: UK£1.29m (up from UK£6.51m loss in FY 2023).
-
Profit margin: 9.3% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
-
EPS: UK£0.004 (up from UK£0.022 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Futura Medical Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) also surpassed analyst estimates by 141%.
Looking ahead, revenue is expected to decline by 29% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the United Kingdom are expected to grow by 5.1%.
Performance of the British Pharmaceuticals industry.
The company's shares are down 2.4% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Futura Medical has 2 warning signs (and 1 which doesn't sit too well with us) we think you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.